In-depth study of CAFs will further elucidate the pathogenesis of bladder cancer, and targeting CAFs-derived CXCL12 may provide a potential therapeutic strategy for bladder cancer. The gene discussed is CXCL12; the disease is urinary bladder carcinoma.